J Korean Diabetes.  2015 Dec;16(4):310-314. 10.4093/jkd.2015.16.4.310.

A Case of Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter 2 Inhibitor

• Jun JH
• Choe KJ
• Woo YM
• Park YR
• Park YK
• Kim WJ
• Shim MS
• Kim JY

• KMID: 2173859
• DOI: http://doi.org/10.4093/jkd.2015.16.4.310

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral antihyperglycemic drugs; inhibition of the cotransporter allows for increased renal glucose excretion that consequently leads to reduced plasma glucose level. We report a rare case of a 73-year-old woman with type 2 diabetes mellitus who developed severe ketoacidosis caused by an SGLT2 inhibitor. At admission, severe ketoacidosis with arterial PH 6.99 was observed, though her serum glucose level of 232 mg/dL was not excessively high. It is necessary to pay attention to patients with type 2 diabetes being treated with an SGLT2 inhibitor, as anorexia, diarrhea, dehydration, and weight loss can develop in conjunction with a high fat/protein diet.

Keyword

Diabetes mellitus; Ketosis; Sodium-glucose cotransporter 2

MeSH Terms

Aged
Anorexia
Blood Glucose
Dehydration
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetic Ketoacidosis*
Diarrhea
Diet
Female
Glucose
Humans
Hydrogen-Ion Concentration
Ketosis
Weight Loss
Glucose

Reference

References

1. Sicree R, Shaw J, Zimmet P. Diabetes atlas. 2nd ed.Brussels: International Diabetes Federation;2003. p. 15–71.

2. Task Force Team For Basic Statistical Study of Korean Diabetes Mellitus. Report of task force team for basic statistical study of Korean diabetes mellitus: diabetes in Korea 2007. 1st ed.Seoul: Goldfishery;2007.

3. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 95:34–42.

4. Hayami T, Kato Y, Kamiya H, Kondo M, Naito E, Sugiura Y, Kojima C, Sato S, Yamada Y, Kasagi R, Ando T, Noda S, Nakai H, Takada E, Asano E, Motegi M, Watarai A, Kato K, Nakamura J. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015; 6:587–90.

5. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375:2223–33.

6. Tridgell DM, Tridgell AH, Hirsch IB. Inpatient management of adults and children with type 1 diabetes. Endocrinol Metab Clin North Am. 2010; 39:595–608.

7. Ennis ED, Stahl EJVB, Kreisberg RA. The hyperosmolar hyperglycaemic syndrome. Diabetes Rev. 1994; 2:115–26.

8. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. American Diabetes Association. Hyperglycemic crises in diabetes. Diabetes Care. 2004; 27(Suppl 1):S94–102.

9. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001; 24:131–53.

10. Kim WJ, Kim SS. The side effects of sodium glucose cotransporter 2 (SGLT2) inhibitor. J Korean Diabetes. 2014; 15:158–62.

11. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D. Tofogliflozin 003 Study Group. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014; 13:65.

12. Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014; 16:137–44.

13. Wright EM, Turk E, Martin MG. Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys. 2002; 36:115–21.